ZAYED-SUSTAINABILITY
29.3.2023 14:15:27 CEST | Business Wire | Press release
The Zayed Sustainability Prize, the UAE’s pioneering global award for recognising excellence in sustainability, has launched a special category called ‘Climate Action.’ This new category is aimed at recognising and promoting innovative solutions that address climate change and protect the planet's natural resources.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230329005548/en/
Employee of Zayed Sustainability Prize winner, Okuafo Foundation, demonstrates how to use a drone to optimise agricultural production (Photo: AETOSWire)
The launch of the Climate Action category coincides with the UAE's Year of Sustainability, a national initiative that aims to accelerate sustainable development across the country in line with the UAE’s national strategy. It also comes ahead of the 28th Conference of the Parties to the UN Framework Convention on Climate Change (COP28), which will be hosted in the UAE later this year.
H.E. Dr. Sultan Ahmed Al Jaber, UAE Minister of Industry and Advanced Technology, Director General of the Zayed Sustainability Prize, and COP28 President-Designate said: “As we mark the UAE's Year of Sustainability and prepare to host COP28, it is more important than ever to recognise and support innovative solutions that protect the planet and people from the impacts of climate change. The UAE is committed to delivering a COP of Action – a solutions-focused COP that promotes inclusive sustainable development and accelerates the adoption of policies that will deliver across mitigation, adaptation, climate finance and loss and damage. The new Climate Action category of the Zayed Sustainability Prize reinforces this commitment by supporting the deployment of solutions the world needs today to keep the Paris Agreement alive and limit warming below 1.5 degrees Celsius.”
H.E. Al Jaber added, “In this critical decade of action, the Climate Action category is a significant addition to the Prize's mandate, and we look forward to receiving submissions from around the world. We are proud to encourage and reward innovative solutions needed to turn climate pledges into concrete action, and drive tangible, inclusive and lasting progress for our planet and communities.”
The Zayed Sustainability Prize was established in 2008 as a tribute to the sustainability and humanitarian legacy of the late Sheikh Zayed bin Sultan Al Nahyan, the Founding Father of the UAE. The Prize recognises organisations and high schools that are delivering impactful, and inspiring innovations across the categories of Health, Food, Energy, Water, Global High Schools and now Climate Action.
The new Climate Action category will further broaden the Prize’s reach and impact by rewarding solutions that protect and enhance the natural environment, while also addressing the urgent challenge of climate change. This includes organisations that promote climate adaptation, build resilience and deploy environmental solutions. Small and medium sized enterprises (SMEs) and nonprofit organisations (NPOs) are eligible to apply to the Climate Action category.
The Zayed Sustainability Prize has a 15-year track record of transforming lives by empowering sustainable solutions across health, food, energy and water. Now, through its special Climate Action category, and as the world’s efforts to fight climate change grows ever larger, the Prize will help scale innovative solutions that tackle environmental problems and enable communities to build climate resilience.
The Zayed Sustainability Prize has become a global platform for promoting sustainable development, with winners and finalists hailing from all corners of the planet. Today, the Prize celebrates 15 years of global impact with over 378 million people around the world benefiting from its 106 winners’ solutions.
The Prize rewards US $600,000 to each winner in the Health, Food, Energy, Water, and Climate Action categories. The Global High Schools category is split into six world regions, with each school able to claim up to US $100,000 to start or further expand their project.
The launch of the Climate Action category is expected to attract a wide range of submissions from around the world. The Zayed Sustainability Prize is calling for entries from nonprofit organisations and small and medium sized enterprises from now until 23 May 2023. The winners will be announced at an awards ceremony in Abu Dhabi.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230329005548/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
